149 related articles for article (PubMed ID: 34915055)
1. Targeting RAS in neuroblastoma: Is it possible?
Lin L; Miao L; Lin H; Cheng J; Li M; Zhuo Z; He J
Pharmacol Ther; 2022 Aug; 236():108054. PubMed ID: 34915055
[TBL] [Abstract][Full Text] [Related]
2.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
3. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
4. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
5. RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.
Eleveld TF; Schild L; Koster J; Zwijnenburg DA; Alles LK; Ebus ME; Volckmann R; Tijtgat GA; van Sluis P; Versteeg R; Molenaar JJ
Cancer Res; 2018 Nov; 78(21):6297-6307. PubMed ID: 30115695
[TBL] [Abstract][Full Text] [Related]
6. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
7. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Eleveld TF; Oldridge DA; Bernard V; Koster J; Colmet Daage L; Diskin SJ; Schild L; Bentahar NB; Bellini A; Chicard M; Lapouble E; Combaret V; Legoix-Né P; Michon J; Pugh TJ; Hart LS; Rader J; Attiyeh EF; Wei JS; Zhang S; Naranjo A; Gastier-Foster JM; Hogarty MD; Asgharzadeh S; Smith MA; Guidry Auvil JM; Watkins TB; Zwijnenburg DA; Ebus ME; van Sluis P; Hakkert A; van Wezel E; van der Schoot CE; Westerhout EM; Schulte JH; Tytgat GA; Dolman ME; Janoueix-Lerosey I; Gerhard DS; Caron HN; Delattre O; Khan J; Versteeg R; Schleiermacher G; Molenaar JJ; Maris JM
Nat Genet; 2015 Aug; 47(8):864-71. PubMed ID: 26121087
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeting therapies for neuroblastoma: Progress and challenges.
Zafar A; Wang W; Liu G; Wang X; Xian W; McKeon F; Foster J; Zhou J; Zhang R
Med Res Rev; 2021 Mar; 41(2):961-1021. PubMed ID: 33155698
[TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Reck M; Carbone DP; Garassino M; Barlesi F
Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
[TBL] [Abstract][Full Text] [Related]
10. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
11. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
12. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.
Naim N; Moukheiber S; Daou S; Kourie HR
Crit Rev Oncol Hematol; 2021 Dec; 168():103524. PubMed ID: 34800654
[TBL] [Abstract][Full Text] [Related]
13. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
14. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Shukla N; Ameur N; Yilmaz I; Nafa K; Lau CY; Marchetti A; Borsu L; Barr FG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(3):748-57. PubMed ID: 22142829
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.
Cannataro VL; Gaffney SG; Stender C; Zhao ZM; Philips M; Greenstein AE; Townsend JP
Oncogene; 2018 May; 37(18):2444-2455. PubMed ID: 29453361
[TBL] [Abstract][Full Text] [Related]
16. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
17. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
Stites EC; Shaw AS
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
[TBL] [Abstract][Full Text] [Related]
18. The path to the clinic: a comprehensive review on direct KRAS
Kwan AK; Piazza GA; Keeton AB; Leite CA
J Exp Clin Cancer Res; 2022 Jan; 41(1):27. PubMed ID: 35045886
[TBL] [Abstract][Full Text] [Related]
19. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
20. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]